Challenges and directions for medicare ESRD payment policy

Seminars in Nephrology

Volumn 20, Issue 6, 2000, Pages 565-576

  Ray, N F ^a   Ross, M ^a  

^a Medicare Payment Advisory Commission   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; KIDNEY FAILURE; MEDICARE; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; REVIEW;

HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; KIDNEY FAILURE, CHRONIC; MEDICARE; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 0033696293     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98
2. Renex. Form 10-Q
3. Total Renal Care. Form 10-K/A
4. Relative risk and economic consequences of inpatient care among patients with renal failure
5. Nightly home hemodialysis (NHHD)
6. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs
7. Improved urea reduction ratio and Kt/V in large hemodialysis patients using two dialyzers in parallel
8. Healthcare and end-stage renal disease (ESRD) therapies - An international review: Costs and reimbursement/funding of ESRD therapies
9. Modified capitation and treatment incentives for end stage renal disease
10. Development of an end-stage renal disease managed care demonstration
11. Barriers to cacaveric renal transplantation among blacks, women, and the poor
12. An examination of the renal transplant evaluation process focusing on cost and the reasons for patient exclusion
13. Race and socio-economic factors influencing early placement or the kidney transplant waiting list
14. Factors determining the rate of referral, transplantation, and survival on dialysis in women with ESRD
15. Unequal access to cadaveric kidney transplantation in California based on insurance status
16. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors
17. Benefits of continued cyclosporine through an indigent drug program
18. Work disability, functional limitations, and the health status of kidney transplantation recipients posttransplant
19. The transplant trap: The impact of health policy on employment status following renal transplantation
20. Effect of transplantation on the Medicare end-stage renal disease program
21. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients
22. Effect of dialyzer reuse on survival of patients treated with hemodialysis
23. Association of dialyzer reuse and hospitalization rates among hemodialysis
24. The Medicare cost of renal dialysis
25. Price of dialysis, unit staffing, and length of dialysis treatments
26. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients
27. The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities
28. The ownership of health facilities and clinical decisionmaking. The case of the ESRD industry
29. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation
30. ESRD Clinical Performance Measures (CPMs) Project
31. RPA launches 3(rd) clinical practice guideline
32. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states
33. Excluded from 'Universal Coverage': End-stage renal disease patients not covered by Medicare